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from Avon Lake, Ohio; Zachary R. Jones, fifth-year pharmacy student from Springfield, Ohio; Zachary Crawford, fifth-year
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This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.
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Objectives
1. Describe why Medication Therapy Management (MTM)
programs would be a vital place to implement
pharmacogenomics.
2. Recognize how a patient's genetic makeup can lead
to significant differences in pharmacokinetics and
pharmacodynamics of certain drugs.
3. Utilize past and current studies of specific drugs and
their pharmacogenomic properties to better assess
patients' medication therapy and avoid preventable
medication errors.
4. Educate other health care professionals on pharmacogenomics and seek to integrate its use into everyday
practice.
Abstract
Incorporation of pharmacogenomic data into Medication
Therapy Management (MTM) allows pharmacists to optimize
treatment regimens for patients leading to better overall outcomes. Utilizing pharmacogenomics makes it easier for
health care professionals to initiate medication regimens
with reduced adverse reactions, improves outcomes due to
specialized dosing and therapies and allows the treatment
process to be as cost-effective as possible for the patient.
Pharmacists have an opportunity to educate the rest of the
health care team on issues such as: which ethnicities possess
higher odds of carrying certain genetic variants, the most
common or most relevant medications that can have variable
effects and medications that have significant severe adverse
effects or hypersensitivities related to specific genetic markers. Using specific examples where medications possess variable efficacy and safety, due to differences in genetics among
the patient population, helps to explain why this is such an
important topic. Medications discussed in the article include
carvedilol (Coreg®), dabigatran (Pradaxa®), methadone
(Dolophine®), clopidogrel (Plavix®), abacavir (Ziagen®), and
carbamazepine (Tegretol®). These examples emphasize why
pharmacogenomic education and testing is not only relevant,
but extremely important, for patients taking certain drugs.
Pharmacists are in a prime position to educate other health
care professionals about new, clinically relevant, pharmacogenomic findings. With knowledge of pharmacogenomics,

8

pharmacists have the opportunity to apply population and
specific individual genetic data into everyday practice, and
thus can improve the efficacy and safety while being more
cost-efficient.

Introduction
Medication Therapy Management (MTM) includes the
evaluation of a patient's complete medication regimen
through a comprehensive medication therapy review, rather
than focusing on one specific medication. 1 Pharmacogenomics (PGx) studies how the genetic make-up of an individual
influences drug absorption, distribution, metabolism and
excretion (i.e., pharmacokinetics) and how the individual
responds to the drug (i.e., pharmacodynamics). This response is measured in terms of the drug's efficacy, and/or
toxicity.z Using pharmacogenomics, health care professionals
will be better able to select a patient's initial medication regimen leading to reduced adverse reactions, improved outcomes via specialized dosing and therapies and potentially
improved cost-effectiveness. Integration of MTM services
and pharmacogenomic data will allow pharmacists to optimize treatment regimens for patients leading to better overall outcomes. It is estimated that annually in the United
States $177 billion is spent on hospital services associated
with illness and death related to medication errors, including
administration of drugs to patients with certain genetic constitutions that put them at risk for drug toxicity.1 Being able
to incorporate PGx information into practice will allow for a
reduction in adverse effects and complications and, consequently, health care costs. Currently 17 of the top 200 drugs
(8.5 percent) have information in their package labeling regarding pharmacogenomics, including the fifth most prescribed drug, clopidogrel (Plavix®), and the seventh most
prescribed drug, atorvastatin (Lipitor®). In 2011, there were
over 68.9 million prescriptions dispensed for these two
medications alone.3
Research shows that many medications, or classes of medications, have significant interindividual pharmacokinetic and/
or pharmacodynamic variability due in part to genetic variability. Genetic variability in many cases can be related to
changes in efficacy and the risk of adverse events. Pharmacists have a unique opportunity to educate the rest of the
health care team on issues such as: which ethnicities possess
higher odds of being carriers of certain genetic variations,
the most common or most relevant medications affected by
genetics and medications for which significant severe
adverse effects or hypersensitivities are possible and are
influenced by genetics. Pharmacists, as drug experts, have an
obligation to continuously bring forth new pharmacogenomic findings to clinical practice.
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Carvedilol (Coreg®)
The importance of pharmacogenomics can be illustrated by
examining specific medications for which genetic variability
influences efficacy and/or the toxicity profile. Heart failure is
a multi-symptom syndrome with an increasing prevalence.4
The mortality rate with heart failure is significantly high, but
the use of beta adrenergic receptor antagonists (beta blockers) has been able to lower mortality rates significantly.4
There is evidence of significant interpatient variability in
response to beta blockers, indicating "one size does not fit
all." This often leads to a "trial and error" process for selecting the proper beta blocker for use in heart failure patients.
Here, incorporation of pharmacogenomics into MTM helps in
optimizing treatment to reduce mortality and minimize
costs, while improving the quality of life. Carvedilol
(Coreg®) is one of the most commonly prescribed beta
blockers for heart failure treatment. Recent evidence indicates that certain genetic polymorphisms of the P1 and Pz
adrenergic receptors results in reduced carvedilol efficacy.s
Carvedilol exerts its effects by antagonizing Pz adrenergic
receptors while inducing down-regulation of the P1 adrenergic receptors.s This down-regulation of P1 receptors could
possibly sensitize the remaining P1 receptors to agonist
stimulation.s In regards to carvedilol, a combination of two
specific beta adrenergic receptor polymorphisms are responsible for decreased efficacy.s The Gln27 allele of the Gln27Glu
polymorphism of the Pz adrenergic receptor is linked to Pz
receptor down-regulation.s The Arg389-homozygous genotype of the P1 adrenergic receptor is associated with enhanced P1 agonist-stimulated intracellular activity.s Because
carvedilol works mainly on Pz receptors, some antagonizing
activity is lost as a result of down -regulation. Carvedilol may
also induce a state of P1 receptor hypersensitivity to agonist
stimulation alone. A retrospective cohort study showed the
use of carvedilol in heart failure patients with this genetic
constitution was linked to 2.3-fold increase in mortality.s
Dabigatran (Pradaxa®)
A common gene variant, found in 33 percent of Europeans,
has been found to influence bleeding risk associated with the
drug dabigatran (Pradaxa®), but to have no effect on its
antithrombotic efficacy. A single-nucleotide polymorphism,
which is a single nucleotide change in the gene DNA sequence (SNP; rs2244613; the rs number is a specific and consistent reference of a given SNP) of the CESl gene, results in
the decreased conversion of the prodrug to the active form.
Variant alleles that patients possess are associated with
drops in serum trough levels since the drug will not be fully
converted to the active form. A decrease in converted
prodrug relates to a 27 percent decrease in relative bleeding
risk. When risk of major and minor bleeding was assessed,
patients who possessed this SNP were significantly less likely
to bleed than those who did not possess the rs2244613 SNP
and patients who were also randomized to warfarin
(Coumadin®) therapy.6
Methadone (Dolophine®)
Methadone (Dolophine®), a synthetic µ-opioid agonist, is
currently a treatment option for opioid dependence.7 SueJanuary 2013 Volume 4, Issue 1
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cessful methadone maintenance treatment (MMT) blocks the
effects of opioids, reduces drug cravings, prevents relapses,
and prevents adverse reactions.7 B-Arrestin (ARRB2), a
component of many g-coupled protein receptors, is involved
in µ-opioid and dopamine receptor signaling and seems to
possess some genetic variations that are of clinical significance.8 A retrospective cohort study of 278 individuals indicated that single nucleotide polymorphism(s) (SNPs;
rs34230287, rs3786047, rs1045280, and rs2036657) in the
ARRB2 gene are linked to treatment failure in homozygous
individuals, excepting rs34230287.8 The study found the risk
of being a non-responder to MMT increases up to threefold
when these SNPs are present.8 Additionally, a twelvefold
shorter duration since the last positive urine test is also seen
in the homozygous population for the variant alleles of
ARRB2.8 Successful treatment of opioid dependence and
overall quality of life could be significantly improved by
knowing the patients' genetic constitution prior to initiation
of methadone treatment.
Clopidogrel (Plavix®)
Clopidogrel (Plavix®), one of the most commonly prescribed anti-platelet drugs in the United States, is metabolized by a CYP-450 enzyme (CYP2Cl 9), as are other drugs in
the same pharmacologic class. Therefore, SNPs in the
CYP2Cl 9 gene can affect the conversion of the prodrug to its
active form.9 The CYP2Cl 9 gene is highly polymorphic with
more than 25 known variant alleles. 10 For instance, the
CYP2Cl 9*2 variant, found in approximately 15 percent of
Caucasians and Africans and 29 to 35 percent of Asians, is an
inherited autosomal co-dominant trait, which affects a patient's ability to metabolize clopidogrel.10 Patients receiving
clopidogrel as anti-platelet therapy, (especially those who
have coronary artery stents ), who carry a CYP2Cl 9*2 allele
are at higher risk of major adverse cardiovascular events.
Heterozygotic individuals (*1/*2) are considered intermediate metabolizers," while homozygotic individuals (*2/*2) are
considered "poor metabolizers." Regardless, data show that
individuals carrying even one of the *2 loss-of-function alleles is at increased risk of major cardiovascular events.10
Patients possessing two CYP2Cl 9*17 alleles are characterized as ultrarapid metabolizers. This allele is expressed in 3
to 21 percent of patients taking clopidogrel and can significantly increase therapeutic levels of the active drug, which
can
enhance
platelet
inhibition.10
Based
on
substantial data, in April of 2010, the Food and Drug Administration (FDA) issued a "black box" warning for clopidogrel
indicating a link between CYP2Cl 9 genotype and drug
response that could possibly result in diminished drug effectiveness for patients who are poor metabolizers. While the
warning does not state a requirement of genetic testing, it is
highly recommended as the drug's effectiveness may be
altered by a patient's genetic disposition.11
Abacavir (Ziagen®)
Abacavir (Ziagen®) is an effective antiretroviral agent used
in Human Immunodeficiency Virus (HIV) therapy, but has
risks of severe hypersensitivity linked to the HLA B*57:01
gene. In a 2007 study, 38 of 49 patients exposed to abacavir
THE PHARMACY AND WELLNESS REVIEW
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demonstrated tolerance of the drug and were found not to
possess the HLA B*57:01 gene.12 This indicated both a lack of
hypersensitivity reaction in patients not possessing HLA
B*57:01, as well as provided data on the prevalence of this
genetic biomarker in a random population. One year later, in
a separate double-blind, prospective, randomized trial, 1,956
patients with HIV-1 who had no previous exposure to
abacavir were studied to identify the effect of prospective
HLA-B*57:01 screening on incidence of hypersensitivity reaction.13 The patients were split into two groups, one of
which was screened for HLA-B*57:01 while the other was
not. Of those screened, only those patients who tested negative for the gene were given abacavir. In the second group,
every patient was treated with abacavir without genetic
screening. Results showed that none of the screened population had immunologically confirmed hypersensitivity reactions, compared to 2.7 percent in the second group.
Researchers concluded that HLA-B*57:01 screening prior to
initiation of abacavir therapy could reduce the risks of hypersensitivity reaction.13 A more recent study showed that 46
percent of abacavir hypersensitive patients tested HLAB*57:01 positive versus 10 percent of non-hypersensitive
patients. 14 Today, there is an FDA "black box" warning on
abacavir recommending pharmacogenomic testing prior to
initiating this medication.11 HLA-B*57:01 screening is now
considered a standard of care in treating HIV-infected
patients.

genomic findings as well as to help integrate pharmacogenomics into standard health care practice. Pharmacists are
key individuals in the implementation of this practice as they
are the drug experts and are currently working to incorporate pharmacogenomics into their practices, including applications in MTM. Pharmacogenomics can be used to improve
the efficacy, safety and cost-effectiveness of medication therapy. Most recommendations are based on data from reports
of mechanism-based and population-based studies, such as:
patients of Asian descent needing to be screened for HLA8*15:02 before starting carbamazepine, all patients receiving
HLA-B testing prior to initiating abacavir and to monitor patients on clopidogrel due to the potential for cardiovascular
events especially in stent placement patients carrying the
CYP2C19*2 variant. Once the health care system becomes
more integrated, allowing a pharmacist to access and assess
key regions of a patient's genome, personalizing a medicine
plan for each patient will become possible. Because pharmacists are currently providing MTM services to many patients,
incorporating pharmacogenomic information into MTM
seems the logical next step to providing patients with the
safest and most effective medication therapy. Being able to
personalize medication regimens will not only reduce the
number of adverse drug events, but also will reduce the
amount of money spent annually to manage these events
and, most importantly, will lead to better patient outcomes.
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Carbamazepine (Tegretol®)
Carbamazepine (Tegretol®), a drug with indications for
disease states such as seizure disorders, bipolar disorder,
and trigeminal neuralgia, has a risk for hypersensitivity reactions that can range from benign to fatal. Recent studies have
revealed important information about two of the fatal reactions-Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN)-which have mortality rates reaching 30
percent.ts Diagnosis of these conditions requires early recognition and prompt withdrawal of the causative agent (i.e.
carbamazepine). More importantly, these reactions have
shown strong links to the HLA-B*15:02 gene, which is most
prevalent in Asian populations.1s Ferrell et al. reviewed a
study which began in Taiwan in 1996, in 44 of 73 reported
cases of SJS/TEN caused by carbamazepine therapy, patients
tested positive for the HLA-B*15:02 gene. All 44 patients
were Han Chinese, so in 2006 researchers added 16 additional Chinese patients to the study and treated all 60 subjects with carbamazepine. Testing revealed that 59 of the 60
were HLA-B*15:02 positive.is Today, the FDA has
included a guideline on the carbamazepine label strongly
encouraging patients of Asian descent to be tested for the
HLA-B*15:02 variant prior to therapy.is
Conclusion
The medications discussed above are a few key examples of
why pharmacogenomic education and testing is not only
relevant but extremely important for patients taking certain
medications. Although pharmacogenomics has overcome
many obstacles, challenges to implementation still exist.
Pharmacists are in a prime position to educate other health
care professionals about new, clinically relevant pharmaco-
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Assessment Questions
1.

7.

It is estimated that
is spent on hospital services
annually in the United States associated with illness and
death related to medication errors.

2.

Pharmacogenomics

The HLA-8*15:02 gene, associated with carbamazepine
hypersensitivity, is most prevalent in which population?
A. Asian

B. Caucasian
C. African-American
D. Hispanic

A. $53 million
B. $177 billion
C. $98 billion
D. $105 million

_"""'!'....~ml!'!"!'"-

1111111111111111111111111111111

8.

In terms of Pradaxa®, about one in three ___ possess
a gene variant that has been found to - -- - '

Heart-failure patients that possess the variant alleles
associated with ~2 adrenergic receptor down-regulation
and enhanced ~1 agonist-stimulated intracellular
activity are at increased risk of _ _.
A. Carvedilol (Coreg®) toxicity

A. Europeans; influence pain suppression.

B. Carvedilol (Coreg®) therapeutic failure

African-Americans; influence bleeding risk.
C. Hispanics; influence seizure threshold.
D. Europeans; influence bleeding risk.

C. Both of the above
D. None of the above

B.

9.
3.

Patients taking Plavix® as antiplatelet therapy who carry
a CYP2C19*2 allele are at _ _ risk of major adverse
cardiovascular events.
A. Higher
B. Lower
C. No

Which of the following drugs has a "black box" warning
indicating a link between a specific genotype and a
diminished drug response?
A. Abacavir (Ziagen®)
B. Dabigatran (Pradaxa®)

C. Clopidogrel (Plavix®)
D. Methadone (Dolophine®)
5.

In a recent study on abacavir, researchers concluded that
HLA-B*57:01 _ _ prior to initiation of therapy could
____ hypersensitivity reaction.
A. screening; increase the risks of

8. screening; reduce the risks of
C. injection; reduce the risks of
D. screening; have no effect on

6.

These two potentially fatal reactions are associated with
carbamazepine therapy:
A. Stevens-Johnson syndrome (SJS) and profound

neutropenia
B. Gangrene and hemorrhage

C. Hemorrhage and toxic epidermal necrolysis
(TEN)
D. Stevens-Johnson syndrome (SJS) and toxic
epidermal necrolysis (TEN)
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A.
B.
C.
D.

Opioid dependence
Mild pain
Narcolepsy
Chemotherapy-induced nausea and vomiting

10. Why are pharmacists in such a key position in regard
to incorporation of pharmacogenetic data into MTM
services?

D. Intermediate
4.

Methadone maintenance treatment is currently used to
treat what medical condition?

A. Pharmacists, as drug experts, have an obligation
to continuously bring forth new pharmacogenetic
findings to clinical practice.
B. Pharmacists have a unique opportunity to
educate the rest of the health care team on
issues such as: which ethnicities possess higher
frequencies of certain genetic variations; the
most common or most relevant medications
affected by genetics; and medications for
which significant severe adverse effects or
hypersensitivities are possible and are
influenced by genetics.
C. A and B
D. None of the above

ri11.
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Describe why Medication Therapy Management (MTM) programs
would be a vital place to implement pharmacogenomics.

I
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3

4
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Recognize how a patient's genetic makeup can lead to significant
differences in pharmacokinetics and pharmacodynamics of
certain drugs.

I

2

3

4

5

Utilize past and current studies of specific drugs and their
pharmacogenomic properties to better assess patients'
medication therapy and avoid preventable medication errors.

1

2
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4
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Educate other health care professionals on pharmacogenomics
and seek to integrate its use into everyday practice.
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3
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The program met your educational needs.
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Content of the program was interesting.
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The program met the stated goals and objectives:
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A B C D

7.
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2.
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5.
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8.

A B C D

3.

A B C D

6.

A B C D

9.

A B C D
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